Anais Del Curatolo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2149323/publications.pdf

Version: 2024-02-01

1307594 1588992 11 601 7 8 citations g-index h-index papers 11 11 11 1491 docs citations times ranked citing authors all docs

#	Article	ΙF	CITATIONS
1	PTEN: Multiple Functions in Human Malignant Tumors. Frontiers in Oncology, 2015, 5, 24.	2.8	356
2	PTEN expression and function in adult cancer stem cells and prospects for therapeutic targeting. Advances in Biological Regulation, 2014, 56, 66-80.	2.3	77
3	Signaling Intermediates (MAPK and PI3K) as Therapeutic Targets in NSCLC. Current Pharmaceutical Design, 2014, 20, 3944-3957.	1.9	55
4	PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer. Scientific Reports, 2017, 7, 43013.	3.3	44
5	Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models. Journal of Experimental and Clinical Cancer Research, 2018, 37, 140.	8.6	27
6	Emerging Insight into MAPK Inhibitors and Immunotherapy in Colorectal Cancer. Current Medicinal Chemistry, 2017, 24, 1383-1402.	2.4	23
7	Lack of growth inhibitory synergism with combined MAPK/PI3K inhibition in preclinical models of pancreatic cancer. Annals of Oncology, 2017, 28, 2896-2898.	1.2	13
8	Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. Expert Opinion on Drug Discovery, 2013, 8, 1381-1397.	5.0	6
9	Synergistic Growth Inhibitory Activity of Combined Mek/Mtor Pathway Blockade in Pten-Null Cancers. Annals of Oncology, 2014, 25, iv548.	1.2	0
10	Abstract 803: A vertical combination strategy hitting multiple steps along the MAPK cascade: Molecular mechanisms of action and putative genetic determinants of synergism., 2014,,.		0
11	Abstract 2618: PTEN loss as a putative biomarker of synergistic growth inhibitory activity of combined MEK/ERK and PI3K/mTOR pathway blockade. , 2014, , .		O